View Past PerformanceEntropy Neurodynamics バランスシートの健全性財務の健全性 基準チェック /56Entropy Neurodynamicsの総株主資本はA$7.9M 、総負債はA$666.2Kで、負債比率は8.4%となります。総資産と総負債はそれぞれA$9.1MとA$1.1Mです。主要情報8.38%負債資本比率AU$666.24k負債インタレスト・カバレッジ・レシオn/a現金AU$6.43mエクイティAU$7.95m負債合計AU$1.13m総資産AU$9.08m財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Nov 05Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million.Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 165,588,236 Price\Range: AUD 0.034 Discount Per Security: AUD 0.00204 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,823,528 Price\Range: AUD 0.034 Discount Per Security: AUD 0.00204 Transaction Features: Subsequent Direct Listingお知らせ • Sep 16Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025. Location: suite 1.01 117 camberwell road, hawthorn east vic 3123, Australiaお知らせ • Mar 31Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million.Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 137,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 162,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Nov 06Tryptamine Therapeutics Limited Announces Peter Molloy to Resign as Non-Executive Director from the Board, Effective November 8, 2024Tryptamine Therapeutics Limited announced that Non-Executive Director Mr. Peter Molloy will resign from the Board of Directors. Mr. Molloy's resignation follows the Company's strategic placement to raise $6 million to fast track its TRP-8803 (IV-infused psilocin) clinical trial strategy, which has also led to the pending appointment of Dr. Daniel Tillett as a Non-Executive Director. Mr. Molloy has been a member of the Company since September 2020 and was influential in Tryp's growth trajectory. He provided valued support in the Company's transition to the Australian Securities Exchange. Dr. Tillett's appointment and Mr. Molloy's resignation will occur after the conclusion of the Company Annual General Meeting, scheduled for November 8, 2024.お知らせ • Nov 01Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 137,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 162,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Sep 06Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024.お知らせ • Sep 03Tryptamine Therapeutics Limited Announces Chief Financial Officer ChangesTryptamine Therapeutics Limited advised that Mr. Hamish George has been appointed Chief Financial Officer (‘CFO’), effective 1 September 2024. As part of the appointment, previous CFO Mr. Jim O'Neill has resigned. Mr. George is a Director at Bio101 Financial Advisory (‘Bio101’). He has over 10 years of finance and commercial experience working with public and private companies in Australia and abroad. Mr. George currently serves as CFO and Company Secretary for several ASX-listed, private companies and not-for-profits. He holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant. The Company announced that Mr. Jim O'Neill provided wide-ranging support to advance the transition of roles to Mr. George during August 2024, enabling him to be fully engaged as CFO from 1 September 2024.財務状況分析短期負債: TYPT.Fの 短期資産 ( A$8.8M ) が 短期負債 ( A$1.1M ) を超えています。長期負債: TYPT.Fには長期負債はありません。デット・ツー・エクイティの歴史と分析負債レベル: TYPT.F総負債よりも多くの現金を保有しています。負債の削減: TYPT.Fの負債対資本比率は、過去 5 年間で0.07%から8.4%に増加しました。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: TYPT.Fは、現在の フリーキャッシュフロー に基づき、1 年以上にわたって十分な キャッシュランウェイ を有しています。キャッシュランウェイの予測: TYPT.Fは、フリー キャッシュ フローが毎年8.6 % の歴史的率で減少し続ける場合、 1.1年間十分なキャッシュ ランウェイを有しています。健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 21:35終値2026/05/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Entropy Neurodynamics Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Michael HigginsLadenburg Thalmann & Company
お知らせ • Nov 05Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million.Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 165,588,236 Price\Range: AUD 0.034 Discount Per Security: AUD 0.00204 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,823,528 Price\Range: AUD 0.034 Discount Per Security: AUD 0.00204 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 16Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025. Location: suite 1.01 117 camberwell road, hawthorn east vic 3123, Australia
お知らせ • Mar 31Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million.Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 137,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 162,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Nov 06Tryptamine Therapeutics Limited Announces Peter Molloy to Resign as Non-Executive Director from the Board, Effective November 8, 2024Tryptamine Therapeutics Limited announced that Non-Executive Director Mr. Peter Molloy will resign from the Board of Directors. Mr. Molloy's resignation follows the Company's strategic placement to raise $6 million to fast track its TRP-8803 (IV-infused psilocin) clinical trial strategy, which has also led to the pending appointment of Dr. Daniel Tillett as a Non-Executive Director. Mr. Molloy has been a member of the Company since September 2020 and was influential in Tryp's growth trajectory. He provided valued support in the Company's transition to the Australian Securities Exchange. Dr. Tillett's appointment and Mr. Molloy's resignation will occur after the conclusion of the Company Annual General Meeting, scheduled for November 8, 2024.
お知らせ • Nov 01Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 137,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 162,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Sep 06Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024.
お知らせ • Sep 03Tryptamine Therapeutics Limited Announces Chief Financial Officer ChangesTryptamine Therapeutics Limited advised that Mr. Hamish George has been appointed Chief Financial Officer (‘CFO’), effective 1 September 2024. As part of the appointment, previous CFO Mr. Jim O'Neill has resigned. Mr. George is a Director at Bio101 Financial Advisory (‘Bio101’). He has over 10 years of finance and commercial experience working with public and private companies in Australia and abroad. Mr. George currently serves as CFO and Company Secretary for several ASX-listed, private companies and not-for-profits. He holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant. The Company announced that Mr. Jim O'Neill provided wide-ranging support to advance the transition of roles to Mr. George during August 2024, enabling him to be fully engaged as CFO from 1 September 2024.